Compare Moderna, Inc. (MRNA) vs Workday Inc (WDAY) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Workday (WDAY) trades at $174.53, down 5.24% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust revenue growth, reaching $8.45B in 2025 with consistent earnings beats. Recent partnerships and AI product launches, including Workday Learning and FedRAMP authorization, highlight strategic expansion. Analyst consensus remains positive with 55.6% buy ratings despite a recent downgrade from Morgan Stanley on July 21, 2026.

WDAY's outlook is supported by solid fundamentals and AI-driven growth initiatives, though elevated valuation metrics (P/E 56.47) and institutional selling pose risks. The stock faces near-term pressure from overbought technical indicators but maintains long-term potential through enterprise software demand and market leadership in HR/finance solutions.